Diabetes Mellitus: Complications¶
Chapter 417 | Part 12: Endocrinology
KEY CLINICAL POINTS¶
- Diabetic complications are classified into microvascular (retinopathy, neuropathy, nephropathy) and macrovascular (ASCVD, PAD, cerebrovascular disease) categories.
- Chronic hyperglycemia is the primary etiologic factor for microvascular complications, while macrovascular complications involve insulin resistance, dyslipidemia, and inflammation.
- Glycemic control targets vary by age and comorbidities (e.g., HbA1c <7.0–7.5% for elderly patients, <6.5% for preconception care).
- SGLT2 inhibitors and GLP-1 agonists reduce cardiovascular risk and slow CKD progression in type 2 DM.
- Diabetic foot ulcers are a leading cause of amputation, requiring multidisciplinary management including offloading, debridement, and revascularization.
1. DEFINITION & OVERVIEW¶
Diabetes-related complications are categorized into microvascular (retinopathy, neuropathy, nephropathy) and macrovascular (ASCVD, PAD, cerebrovascular disease) complications. Microvascular complications are diabetes-specific, while macrovascular complications share pathophysiology with the general population. Nonvascular complications include infections, skin changes, and cognitive decline.
Table 417-1 Diabetes-Related Complications¶
| Category | Microvascular Complications | Macrovascular Complications |
|---|---|---|
| Eye Disease | Retinopathy (nonproliferative/proliferative), Macular edema | Coronary heart disease, Peripheral arterial disease |
| Neuropathy | Sensory and motor (mono- and polyneuropathy), Autonomic | Cerebrovascular disease, Heart failure |
| Nephropathy | Albuminuria, Declining renal function | |
| Other | Gastrointestinal (gastroparesis, diarrhea), Genitourinary (uropathy/sexual dysfunction) | Other (e.g., diabetic cardiomyopathy) |
1.1 Microvascular Complications¶
Retinopathy, neuropathy, and nephropathy are hallmark microvascular complications. Retinopathy leads to macular edema and neovascularization; neuropathy includes sensory/motor and autonomic dysfunction; nephropathy progresses through albuminuria to end-stage renal disease.
1.2 Macrovascular Complications¶
ASCVD (coronary, peripheral, cerebrovascular) and heart failure are macrovascular complications. Insulin resistance, dyslipidemia, and inflammation drive these complications, often preceding hyperglycemia.
2. EPIDEMIOLOGY¶
Diabetes affects ~374 million globally (2021). Microvascular complications occur in ~50% of patients with long-standing DM; macrovascular complications are more common in type 2 DM. Risk factors include duration of diabetes, poor glycemic control, hypertension, dyslipidemia, and genetic susceptibility. Black, Hispanic, and Native American populations have higher incidence of nephropathy and retinopathy.
2.1 Incidence & Prevalence¶
Type 1 DM: 1 in 300 children; Type 2 DM: 1 in 10 adults. GDM complicates ~7% of pregnancies, with higher rates in Black and Hispanic populations.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Chronic hyperglycemia drives microvascular complications via advanced glycation end products (AGEs), oxidative stress, and endothelial dysfunction. Macrovascular complications arise from insulin resistance, dyslipidemia, and inflammation. Genetic factors influence susceptibility to specific complications.
3.1 Hyperglycemia-Driven Pathways¶
AGEs, oxidative stress, and mitochondrial dysfunction contribute to retinopathy, nephropathy, and neuropathy. VEGF-A overproduction in retinopathy and endothelial dysfunction in nephropathy are key mechanisms.
3.2 Insulin Resistance & Inflammation¶
Insulin resistance in type 2 DM leads to dyslipidemia (small dense LDL, triglycerides), promoting atherosclerosis. Chronic inflammation exacerbates vascular damage and accelerates macrovascular complications.
4. CLINICAL FEATURES¶
Symptoms include visual impairment (retinopathy), neuropathic pain (distal symmetric polyneuropathy), nephrotic syndrome (nephropathy), and cardiovascular symptoms (angina, stroke). Diabetic foot ulcers present with non-healing wounds, infection, and risk of amputation.
4.1 Microvascular Manifestations¶
Retinopathy: Blurred vision, floaters, blindness. Neuropathy: Numbness, tingling, foot ulcers. Nephropathy: Proteinuria, edema, renal failure.
4.2 Macrovascular Manifestations¶
ASCVD: Chest pain, leg pain, stroke. Heart failure: Dyspnea, edema. Diabetic cardiomyopathy: Reduced LV function without CAD.
5. DIFFERENTIAL DIAGNOSIS¶
Retinopathy: Hypertensive retinopathy, age-related macular degeneration. Neuropathy: Lyme disease, HIV, vitamin B12 deficiency. Nephropathy: Glomerulonephritis, hypertension. Diabetic foot ulcers: Venous stasis ulcers, arterial ulcers.
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnosis requires: 1) Glycemic control (HbA1c, fasting glucose), 2) Microvascular assessment (fundoscopy, urine albumin/creatinine ratio), 3) Macrovascular evaluation (ECG, ankle-brachial index), 4) Imaging (MRI for osteomyelitis, DSA for PAD).
6.1 Diagnostic Criteria¶
Retinopathy: Fundoscopic exam, fluorescein angiography. Nephropathy: UACR >30 mg/g creatinine, eGFR <60 mL/min/1.73m². PAD: ABI <0.9.
6.2 Imaging & Biomarkers¶
MRI for foot osteomyelitis, DSA for PAD, OCT for macular edema. Biomarkers: Cystatin C for renal function, hsCRP for inflammation.
7. MANAGEMENT & TREATMENT¶
Lifestyle modification (diet, exercise) and glycemic control (HbA1c <7%) are foundational. Pharmacologic agents include SGLT2 inhibitors, GLP-1 agonists, ACE/ARBs, and statins. Multidisciplinary care is essential for foot ulcers and cardiovascular disease.
7.1 Glycemic Control¶
HbA1c targets: <7.0% for most adults, <6.5% for preconception care. Avoid hypoglycemia in elderly patients. Insulin analogs preferred for severe hyperglycemia.
7.2 Pharmacologic Therapies¶
SGLT2 inhibitors (empagliflozin, dapagliflozin) reduce cardiovascular risk. GLP-1 agonists (semaglutide) improve kidney outcomes. ACE/ARBs for hypertension and nephropathy. Statins for ASCVD.
7.3 Foot Ulcer Management¶
Offloading, debridement, revascularization, and antibiotics for infection. Advanced therapies: Negative pressure wound therapy, hyperbaric oxygen.
8. PROGNOSIS & COMPLICATIONS¶
Diabetic complications are leading causes of blindness, renal failure, and amputation. Cardiovascular mortality is 2–4x higher in type 2 DM. Metabolic memory suggests long-term benefits of early glycemic control. Poor glycemic control increases risk of retinopathy, nephropathy, and neuropathy.
8.1 Long-Term Outcomes¶
DCCT/UKPDS showed 5.1-year survival benefit with intensive glycemic control. CKD progression is slowed by SGLT2 inhibitors and finerenone.
8.2 Complication Risks¶
Diabetic foot ulcers: 14–24% amputation risk. Diabetic neuropathy: 50% prevalence in type 1/2 DM. ASCVD: 2x higher incidence in DM patients.
9. SPECIAL CONSIDERATIONS¶
Pregnancy: Gestational diabetes (GDM) increases future T2DM risk. Preconception care requires HbA1c <6.5%. Elderly patients need cautious glycemic targets to avoid hypoglycemia. CKD patients require SGLT2 inhibitor caution due to euglycemic ketoacidosis risk.
9.1 Pregnancy & GDM¶
Screen for GDM at 24–28 weeks. Insulin is preferred; metformin/glyburide may be used. GDM increases T2DM risk by 5–10%.
9.2 CKD Management¶
SGLT2 inhibitors reduce CKD progression but require eGFR >30 mL/min/1.73m². Finerenone lowers hyperkalemia risk in CKD.
10. KEY POINTS & CLINICAL PEARLS¶
- Intensive glycemic control reduces microvascular complications by 40–50%. 2. SGLT2 inhibitors and GLP-1 agonists improve cardiovascular and renal outcomes. 3. Diabetic foot ulcers require multidisciplinary care to prevent amputation. 4. Metabolic memory suggests long-term benefits of early glycemic control. 5. CKD patients need SGLT2 inhibitor caution due to euglycemic ketoacidosis risk.